Affiliations 

  • 1 Department of Endocrinology, Skane University Hospital, Malmö, Sweden
  • 2 BD Diabetes Care, Franklin Lakes, NJ
  • 3 University of Liege, Liege, Belgium
  • 4 BD, Le Pont de Claix, France
  • 5 BD Diabetes Care, Erembodegem, Belgium. Electronic address: kenneth_strauss@europe.bd.com
Mayo Clin Proc, 2016 Sep;91(9):1224-30.
PMID: 27594186 DOI: 10.1016/j.mayocp.2016.06.012

Abstract

From February 1, 2014, through June 30, 2015, 13,289 insulin-injecting patients from 423 centers in 42 countries participated in one of the largest surveys ever performed in diabetes. The first results of this survey are published elsewhere in this issue. Herein we report that the most common complication of injecting insulin is lipohypertrophy (LH), which was self-reported by 29.0% of patients and found by physical examination in 30.8% by health care professionals (HCPs). Patients with LH consumed a mean of 10.1 IU more insulin daily than patients without LH. Glycated hemoglobin levels averaged 0.55% higher in patients with vs without LH. Lipohypertrophy was associated with higher rates of unexplained hypoglycemia and glycemic variability as well as more frequent diabetic ketoacidosis, incorrect rotation of injection sites, use of smaller injection zones, longer duration of insulin use, and reuse of pen needles (each P

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.